PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
87.35%
Revenue growth above 1.5x CVE's 4.96%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
167.60%
Positive gross profit growth while CVE is negative. John Neff would see a clear operational edge over the competitor.
626.67%
Positive EBIT growth while CVE is negative. John Neff might see a substantial edge in operational management.
626.67%
Positive operating income growth while CVE is negative. John Neff might view this as a competitive edge in operations.
269.37%
Net income growth above 1.5x CVE's 4.68%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
267.80%
EPS growth above 1.5x CVE's 4.35%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
268.94%
Diluted EPS growth above 1.5x CVE's 4.35%. David Dodd would see if there's a robust moat protecting these shareholder gains.
0.77%
Slight or no buybacks while CVE is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
-0.01%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
-27.09%
Both companies cut dividends. Martin Whitman would look for a common factor, such as cyclical downturn or liquidity constraints.
63.91%
Positive OCF growth while CVE is negative. John Neff would see this as a clear operational advantage vs. the competitor.
77.45%
FCF growth under 50% of CVE's 626.09%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
48.21%
10Y revenue/share CAGR at 75-90% of CVE's 59.00%. Bill Ackman would press for new markets or product lines to narrow the gap.
-72.38%
Negative 5Y CAGR while CVE stands at 59.00%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
35.33%
3Y revenue/share CAGR similar to CVE's 37.71%. Walter Schloss would assume both companies experience comparable short-term cycles.
-20.66%
Negative 10Y OCF/share CAGR while CVE stands at 3.75%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-71.73%
Negative 5Y OCF/share CAGR while CVE is at 3.75%. Joel Greenblatt would question the firm’s operational model or cost structure.
-37.84%
Negative 3Y OCF/share CAGR while CVE stands at 74.84%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
64.92%
Net income/share CAGR above 1.5x CVE's 11.16% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
-39.07%
Negative 5Y net income/share CAGR while CVE is 11.16%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
244.85%
3Y net income/share CAGR above 1.5x CVE's 3.51%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
-17.51%
Negative equity/share CAGR over 10 years while CVE stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-74.01%
Negative 5Y equity/share growth while CVE is at 0.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-68.30%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
305.40%
Dividend/share CAGR of 305.40% while CVE is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
-63.33%
Negative 5Y dividend/share CAGR while CVE stands at 0.00%. Joel Greenblatt sees a weaker commitment to dividends vs. a competitor that might be growing them.
-26.38%
Negative near-term dividend growth while CVE invests at 21.34%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
-13.44%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
-19.51%
Inventory is declining while CVE stands at 11.22%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
0.54%
Asset growth above 1.5x CVE's 0.07%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
12.03%
BV/share growth above 1.5x CVE's 0.79%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-0.22%
We’re deleveraging while CVE stands at 3.56%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
-6.00%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.